- Home
- DXCM vs ROIV Comparison
DXCM vs ROIV Comparison
Compare DXCM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | ROIV |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4B | 28.7B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXCM | ROIV |
|---|---|---|
| Price | $87.32 | $34.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 29 | 13 |
| Target Price | ★ $96.46 | $48.27 |
| AVG Volume (30 Days) | 3.5M | ★ 6.4M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.18 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $12.17 | $530.75 |
| Revenue Next Year | $10.78 | $685.92 |
| P/E Ratio | $72.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.11 | $16.89 |
| 52 Week High | $92.59 | $42.50 |
Technical Indicators
Market Signals| Indicator | DXCM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 39.68 |
| Support Level | $87.51 | $33.15 |
| Resistance Level | $91.77 | $37.59 |
| Average True Range (ATR) | 2.12 | 1.15 |
| MACD | -0.01 | -0.29 |
| Stochastic Oscillator | 96.22 | 24.17 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.